精密医療市場は、12.1%のCAGRで成長し、1,386億ドルに達すると予想されます。ゲノミクスと遺伝子配列技術の進歩が、精密医療分野の現在の目覚ましい拡大の主な原因となっています。これらの開発によって、疾患に関連する遺伝的差異を見つけて、その後個別の治療を提供することが容易になります。精密医療は腫瘍学以外でも用途を見出しており、診断機器やバイオマーカー検査の需要が高まっています。治療決定の精度も、実質的な患者データの組み込みとデータ分析のための人工知能の使用によって向上しています。精密医療は、規制当局の支援とガイドラインの継続的な進化のおかげで、患者のケアと転帰を改善するためのダイナミックで有望な戦略として位置付けられています。
目次
Table of Content
1. Executive Summary
1.1. Regional Market Share
1.2. Business Trends
1.3. Precision Medicine Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2. Research Methodology
2.1. Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3. Market Characteristics
3.1. Market Definition
3.2. Precision Medicine Market: COVID-19 Impact
3.3. Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4. Precision Medicine Market - Industry Insights
4.1. Industry Segmentation
4.2. COVID-19 overview on world economy
4.3. Industry ecosystem Channel analysis
4.4. Innovation & Sustainability
5. Macroeconomic Indicators
6. Recent Developments
7. Market Dynamics
7.1. Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4. Market Restraints
7.5. Market Trends
8. Risk Analysis
9. Market Analysis
9.1. Porters Five Forces
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10. Precision Medicine Market
10.1. Overview
10.2. Historical Analysis (2019-2021)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11. Precision Medicine Market Size & Forecast 2022A-2032F
11.1. Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Type
11.3.1.1. Inhibitors
11.3.1.1.1. By Value (USD Million) 2022-2032F
11.3.1.1.2. Market Share (%) 2022-2032F
11.3.1.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.2. Monoclonal Antibodies
11.3.1.2.1. By Value (USD Million) 2022-2032F
11.3.1.2.2. Market Share (%) 2022-2032F
11.3.1.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.3. Cell & Gene Therapy
11.3.1.3.1. By Value (USD Million) 2022-2032F
11.3.1.3.2. Market Share (%) 2022-2032F
11.3.1.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.4. Antivirals
11.3.1.4.1. By Value (USD Million) 2022-2032F
11.3.1.4.2. Market Share (%) 2022-2032F
11.3.1.4.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.5. Antiretroviral
11.3.1.5.1. By Value (USD Million) 2022-2032F
11.3.1.5.2. Market Share (%) 2022-2032F
11.3.1.5.3. Y-o-Y Growth (%) 2022-2032F
11.3.2. By Application
11.3.2.1. Oncology
11.3.2.1.1. By Value (USD Million) 2022-2032F
11.3.2.1.2. Market Share (%) 2022-2032F
11.3.2.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.2.2. Rare Disease
11.3.2.2.1. By Value (USD Million) 2022-2032F
11.3.2.2.2. Market Share (%) 2022-2032F
11.3.2.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.2.3. Hematology
11.3.2.3.1. By Value (USD Million) 2022-2032F
11.3.2.3.2. Market Share (%) 2022-2032F
11.3.2.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.2.4. Infectious
11.3.2.4.1. By Value (USD Million) 2022-2032F
11.3.2.4.2. Market Share (%) 2022-2032F
11.3.2.4.3. Y-o-Y Growth (%) 2022-2032F
11.3.2.5. Others
11.3.2.5.1. By Value (USD Million) 2022-2032F
11.3.2.5.2. Market Share (%) 2022-2032F
11.3.2.5.3. Y-o-Y Growth (%) 2022-2032F
11.3.3. By Technology
11.3.3.1Genomics
11.3.3.1.1 By Value (USD Million) 2022-2032F
11.3.3.1.2Market Share (%) 2022-2032F
11.3.3.1.3Y-o-Y Growth (%) 2022-2032F
11.3.3.2Transcriptomics and Epigenomics
11.3.3.2.1By Value (USD Million) 2022-2032F
11.3.3.2.2 Market Share (%) 2022-2032F
11.3.3.3.1Y-o-Y Growth (%) 2022-2032F
11.3.3.3Others
11.3.3.3.1By Value (USD Million) 2022-2032F
11.3.4.1.2Market Share (%) 2022-2032F
11.3.4.1.3Y-o-Y Growth (%) 2022-2032F
11.3.4By End Users
11.3.4.1 Hospitals and Clinics
11.3.4.1.1 By Value (USD Million) 2022-2032F
11.3.4.1.2Market Share (%) 2022-2032F
11.3.4.1.3Y-o-Y Growth (%) 2022-2032F
11.3.4.2Homecare
11.3.4.2.1By Value (USD Million) 2022-2032F
11.3.4.2.2 Market Share (%) 2022-2032F
11.3.4.2.3 Y-o-Y Growth (%) 2022-2032F
12. North America Precision Medicine Market Size & Forecast 2022A-2032F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Technology
12.3.2. By End Users
12.3.3. By Type
12.3.4. By Application
12.4. Country
12.4.1. United States
12.4.2. Canada
13. Europe Precision Medicine Market Size & Forecast 2022A-2032F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Technology
13.3.2. By End Users
13.3.3. By Type
13.3.4. By Application
13.4. Country
13.4.1. Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14. Asia-Pacific Precision Medicine Market Size & Forecast 2022A-2032F
14.1. Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Technology
14.3.2. By End Users
14.3.3. By Type
14.3.4. By Application
14.4. Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15. Middle East and Africa Precision Medicine Market Size & Forecast 2022A-2032F
15.1. Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Technology
15.3.2. By End Users
15.3.3. By Type
15.3.4. By Application
15.4. Country
15.4.1. Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4. South Africa
15.4.5. Rest of Middle East and Africa
16. Latin America Precision Medicine Market Size & Forecast 2022A-2032F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Technology
16.3.2. By End Users
16.3.3. By Type
16.3.4. By Application
16.4. Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17. Competitive Landscape
17.1. Company market share, 2021
17.2. Key player overview
17.3. Key stakeholders
18. Company Profiles
18.1. Illumina, Inc.
18.1.1. Company Overview
18.1.2. Financial Overview
18.1.3. Key Product; Analysis
18.1.4. Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2. Thermo Fisher Scientific, Inc.
18.3. Roche Holding AG
18.4. Qiagen N. V.
18.5. Myriad Genetics, Inc.
18.6. Exact Sciences Corporation
18.7. Bristol-Myers Squibb
18.8. Novartis AG
18.9. Amgen Inc.
18.10. AstraZeneca PLC
18.11. Gilead Sciences, Inc.
18.12. Bio-Rad Laboratories, Inc.
18.13. Foundation Medicine, Inc.
18.14. Becton, Dickinson and Company (BD)
18.15. Tempus, Inc.
18.16. Other Prominent Players
19. Appendix
20. Consultant Recommendation
